抗菌和抗疟治疗剂:专利视角。

IF 1.2 Q4 PHARMACOLOGY & PHARMACY
Hai-Long Zhang, Yongxia Li
{"title":"抗菌和抗疟治疗剂:专利视角。","authors":"Hai-Long Zhang, Yongxia Li","doi":"10.2174/0127722708268538231010041307","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Antibacterial and antimalarial drugs play a critical role in combating infectious diseases. It is a continuous work to develop new types of antibacterial and antimalarial drugs.</p><p><strong>Objective: </strong>To better understand current landscape and association of antibacterial and antimalarial agents, the European patent analysis was performed.</p><p><strong>Methods: </strong>Antibacterial and antimalarial agents were analyzed by patent analysis. Patent documents from January 2003 to May 2022 were retrieved and analyzed.</p><p><strong>Results: </strong>The present study indicated there were virtually three therapeutic approaches for antibacterial agents, including chemical drugs, biological products and siRNA technology. Chemical drugs were a mainstream therapeutic approach for development of both antibacterial and antimalarial agents. However, the present study found that in contrast to antimalarials, siRNA technology had been initially explored as therapeutic strategy for antibacterial agents. Also, our study is the first to show that there is a low correlation between antibacterial and antimalarial agents.</p><p><strong>Conclusion: </strong>Globally, our study is the first one to show that it may be not a fast approach to discover antimalarial drugs from antibacterial agents based on drug repurposing. siRNA technology as therapeutic strategy had been explored and used in antibacterial field.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"57-66"},"PeriodicalIF":1.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antibacterial and Antimalarial Therapeutic Agents: A Patent Perspective.\",\"authors\":\"Hai-Long Zhang, Yongxia Li\",\"doi\":\"10.2174/0127722708268538231010041307\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Antibacterial and antimalarial drugs play a critical role in combating infectious diseases. It is a continuous work to develop new types of antibacterial and antimalarial drugs.</p><p><strong>Objective: </strong>To better understand current landscape and association of antibacterial and antimalarial agents, the European patent analysis was performed.</p><p><strong>Methods: </strong>Antibacterial and antimalarial agents were analyzed by patent analysis. Patent documents from January 2003 to May 2022 were retrieved and analyzed.</p><p><strong>Results: </strong>The present study indicated there were virtually three therapeutic approaches for antibacterial agents, including chemical drugs, biological products and siRNA technology. Chemical drugs were a mainstream therapeutic approach for development of both antibacterial and antimalarial agents. However, the present study found that in contrast to antimalarials, siRNA technology had been initially explored as therapeutic strategy for antibacterial agents. Also, our study is the first to show that there is a low correlation between antibacterial and antimalarial agents.</p><p><strong>Conclusion: </strong>Globally, our study is the first one to show that it may be not a fast approach to discover antimalarial drugs from antibacterial agents based on drug repurposing. siRNA technology as therapeutic strategy had been explored and used in antibacterial field.</p>\",\"PeriodicalId\":29815,\"journal\":{\"name\":\"Recent Advances in Inflammation & Allergy Drug Discovery\",\"volume\":\" \",\"pages\":\"57-66\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recent Advances in Inflammation & Allergy Drug Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0127722708268538231010041307\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent Advances in Inflammation & Allergy Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0127722708268538231010041307","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:抗菌和抗疟药物在对抗传染病方面发挥着至关重要的作用。开发新型抗菌和抗疟药物是一项持续的工作。目的:为了更好地了解抗菌和抗疟药物的现状和关联,进行了欧洲专利分析。方法:采用专利分析法对抗菌、抗疟药物进行分析。检索并分析了2003年1月至2022年5月的专利文献。结果:本研究表明,抗菌剂的治疗方法实际上有三种,包括化学药物、生物制品和siRNA技术。化学药物是开发抗菌和抗疟药物的主流治疗方法。然而,本研究发现,与抗疟药物相比,siRNA技术最初被探索为抗菌药物的治疗策略。此外,我们的研究首次表明,抗菌剂和抗疟剂之间的相关性很低。结论:在全球范围内,我们的研究首次表明,基于药物再利用从抗菌剂中发现抗疟药物可能不是一种快速的方法。siRNA技术作为一种治疗策略已经在抗菌领域得到了探索和应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Antibacterial and Antimalarial Therapeutic Agents: A Patent Perspective.

Background: Antibacterial and antimalarial drugs play a critical role in combating infectious diseases. It is a continuous work to develop new types of antibacterial and antimalarial drugs.

Objective: To better understand current landscape and association of antibacterial and antimalarial agents, the European patent analysis was performed.

Methods: Antibacterial and antimalarial agents were analyzed by patent analysis. Patent documents from January 2003 to May 2022 were retrieved and analyzed.

Results: The present study indicated there were virtually three therapeutic approaches for antibacterial agents, including chemical drugs, biological products and siRNA technology. Chemical drugs were a mainstream therapeutic approach for development of both antibacterial and antimalarial agents. However, the present study found that in contrast to antimalarials, siRNA technology had been initially explored as therapeutic strategy for antibacterial agents. Also, our study is the first to show that there is a low correlation between antibacterial and antimalarial agents.

Conclusion: Globally, our study is the first one to show that it may be not a fast approach to discover antimalarial drugs from antibacterial agents based on drug repurposing. siRNA technology as therapeutic strategy had been explored and used in antibacterial field.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
33
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信